| scholarly article | Q13442814 |
| P50 | author | Rebeca Northland | Q115057490 |
| P2093 | author name string | Grace M Thorne | |
| Jeff Alder | |||
| Robert D Arbeit | |||
| Patricia Bernardo | |||
| Peter E Pertel | |||
| Peter Matthews | |||
| Charles Fogarty | |||
| Mark Benvenuto | |||
| Steven A Luperchio | |||
| P2860 | cites work | A prediction rule to identify low-risk patients with community-acquired pneumonia | Q28301165 |
| Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults | Q34077164 | ||
| Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study | Q34579869 | ||
| Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens | Q35701450 | ||
| Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. | Q40478153 | ||
| STUDIES ON PNEUMONIA IN CHILDREN: I. Mortality, Blood Cultures, and Humoral Antibodies in Pneumococcus Pneumonia | Q40923190 | ||
| Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus | Q44728502 | ||
| Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia | Q44989661 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults | Q46763833 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ceftriaxone | Q421713 |
| P304 | page(s) | 1142-1151 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia | |
| P478 | volume | 46 |
| Q42678955 | A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia |
| Q40239326 | A Tick Antivirulence Protein Potentiates Antibiotics against Staphylococcus aureus |
| Q37263289 | A current perspective on daptomycin for the clinical microbiologist |
| Q38233287 | Antibacterial drug development: challenges, recent developments, and future considerations |
| Q40631566 | Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections |
| Q57153846 | Antimicrobial Therapy in Community-Acquired Pneumonia in Children |
| Q51856713 | Antimicrobial stewardship in the intensive care unit: advances and obstacles. |
| Q42372253 | Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents |
| Q37291341 | Antimicrobial-resistant Streptococcus pneumoniae: trends and management |
| Q38172440 | Assessment of bias in outcomes reported in trials on pneumonia: a systematic review |
| Q60955298 | Assessment of the Perceived Acceptability of an Early Enrollment Strategy Using Advance Consent in Health Care-Associated Pneumonia |
| Q34726283 | Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE. |
| Q41582554 | Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial |
| Q31033921 | Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials |
| Q47677515 | Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial |
| Q33741018 | Challenges of antibacterial discovery revisited |
| Q30860363 | Chapter 20. Biosynthesis and genetic engineering of lipopeptides in Streptomyces roseosporus |
| Q37849391 | Clinical management of Staphylococcus aureus bacteraemia |
| Q45303679 | Comment on: Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials |
| Q22241379 | Community acquired bacterial pneumonia |
| Q83649158 | Community-acquired pneumonia |
| Q26853465 | Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci |
| Q26863225 | Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria |
| Q35771368 | Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus |
| Q37150644 | Daptomycin for the treatment of major gram-positive infections after cardiac surgery. |
| Q37762644 | Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery |
| Q35215307 | Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia |
| Q42411102 | Development of a Genetic System for Combinatorial Biosynthesis of Lipopeptides in Streptomyces fradiae and Heterologous Expression of the A54145 Biosynthesis Gene Cluster |
| Q37682916 | Diagnosis and management of community-associated MRSA infections in children |
| Q91713397 | Duration of Antibiotic Therapy: Shorter Is Better |
| Q36115620 | Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials |
| Q27000445 | Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials |
| Q24656785 | Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae |
| Q37864327 | Emerging drugs for pneumococcal pneumonia |
| Q38011845 | Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports |
| Q26823518 | European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid |
| Q43957365 | FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia |
| Q33768851 | Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties |
| Q42963295 | Genomics and the ancient origins of the daptomycin biosynthetic gene cluster |
| Q36281234 | Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations |
| Q36999966 | Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves |
| Q38915822 | Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antib |
| Q39910428 | Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. |
| Q92880909 | Intravenous Ceftriaxone Versus Multiple Dosing Regimes of Intravenous Anti-Staphylococcal Antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA): A Systematic Review |
| Q57237808 | Management of Community-acquired Pneumonia in Adults |
| Q88924840 | Methicillin-resistant Staphylococcus aureus |
| Q26822729 | Multidrug-resistant bacteria in solid organ transplant recipients |
| Q37636913 | New antibiotics: optimal use in current clinical practice |
| Q38358209 | Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia |
| Q33684318 | Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia |
| Q54400668 | Production of novel lipopeptide antibiotics related to A54145 by Streptomyces fradiae mutants blocked in biosynthesis of modified amino acids and assignment of lptJ, lptK and lptL gene functions |
| Q41987708 | Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. |
| Q36486840 | Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes |
| Q34470298 | Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia |
| Q34165319 | Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia |
| Q33798268 | Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin |
| Q38202574 | Respiratory infections |
| Q82577811 | Structural characterization of a lipopeptide antibiotic A54145E(Asn3Asp9) produced by a genetically engineered strain of Streptomyces fradiae |
| Q37955286 | Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia |
| Q34699108 | Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens |
| Q49692552 | The Maturing Antibiotic Mantra: "Shorter Is Still Better". |
| Q27015976 | Treatment of Gram-positive infections in critically ill patients |
| Q36854025 | White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens |
Search more.